Nov. 17, 2017 — In response to an Office of Prescription Drug Promotion (OPDP) call for input on a “limited risks plus disclosure” strategy for broadcast direct-to-consumer (DTC) ads, the FDA received 39 comments from health professionals and consumers as of Nov. 16. Although several of the commenters call for a complete ban on DTC […]
Read more
Aug. 11, 2017 – The results of a recent study conducted by the FDA and RTI International has concluded that a revised, briefer risk statement in broadcast direct-to-consumer (DTC) ads improves risk and benefit recognition and risk recall. As such, a move toward communicating a limited number of risks and including a disclosure alerting consumers […]
Read moreFeb. 17, 2014 – In recognition that the stream of risks currently disclosed on direct-to-consumer (DTC) television ads may be so detailed that they have become white noise, the FDA is announcing in the Federal Register due to be published Feb. 18 (2014-03390) that it will study what impact limiting those risks to the most serious […]
Read more